Compare BIO-TECHNE Corp (TECH) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United States Natural Gas Fund — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while United States Natural Gas Fund trades at $10.42. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while United States Natural Gas Fund pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| TECH | UNG | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Commodities - Energy |
52-Week High | $72.12 | $16.90 |
52-Week Low | $43.31 | $10.15 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
UNG trades at $10.29, down 2.09% in the last session, with technical indicators signaling a bearish trend. The stock shows oversold conditions on short-term RSI readings but faces strong selling pressure from moving averages. Recent news highlights volatility in natural gas futures, with prices influenced by weather forecasts and LNG demand fluctuations. Fundamental data is unavailable, limiting traditional valuation analysis.
The outlook remains cautious due to commodity price dependency and lack of fundamental metrics. Risks include energy market volatility and competition from equity-based natural gas ETFs. Analyst sentiment is mixed, with technicals leaning bearish but potential for short-term rebounds if gas prices stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
